Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL.
10.7534/j.issn.1009-2137.2016.02.059
- Author:
Yu-Jiao HOU
1
;
Li ZHAO
2
;
Xiang-Xing LIU
1
;
Yun-Yun MA
1
Author Information
1. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Central Laboratory, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. E-mail: zhaoli@lzu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Mercaptopurine;
therapeutic use;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy;
Thioguanine;
therapeutic use
- From:
Journal of Experimental Hematology
2016;24(2):622-626
- CountryChina
- Language:Chinese
-
Abstract:
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Despite good remission rate has achieved nowadays, the patients still face a substantial risk of relapse. It has long been recognized that thiopurines are critical components in the treatment for prevention of recurrence in childhood ALL, the 6-mercaptopurine (6-MP) has usually been used in daily long-term maintenance therapy, and 6-thioguanine (6-TG) limited to the reinforcement of therapy. However, there is no optimal regimen for 6-TG or 6-MP. The related research advances on the clinical effectiveness of the two thiopurines are reviewed.
